Shenzhen YHLO Biotech Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shenzhen YHLO Biotech Co., Ltd.

Why is Shenzhen YHLO Biotech Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -17.89% and Operating profit at -39.30% over the last 5 years

The company has declared negative results for the last 9 consecutive quarters

The company has declared negative results in Mar 23 after 2 consecutive negative quarters
NET PROFIT(HY) At CNY 62.04 MM has Grown at -61.39%
INTEREST(HY) At CNY 9.77 MM has Grown at 35.57%
OPERATING CASH FLOW(Y) Lowest at CNY 286.13 MM

With ROE of 6.88%, it has a expensive valuation with a 3.06 Price to Book Value

Over the past year, while the stock has generated a return of -18.54%, its profits have fallen by -46.6%

Below par performance in long term as well as near term

Along with generating -18.54% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shenzhen YHLO Biotech Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Shenzhen YHLO Biotech Co., Ltd.

-11.06%

-1.82

24.54%

China Shanghai Composite

16.67%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-17.89%

EBIT Growth (5y)

-39.30%

EBIT to Interest (avg)

50.60

Debt to EBITDA (avg)

0.13

Net Debt to Equity (avg)

0.09

Sales to Capital Employed (avg)

0.61

Tax Ratio

11.06%

Dividend Payout Ratio

39.64%

Pledged Shares

Institutional Holding

ROCE (avg)

24.88%

ROE (avg)

18.68%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.06

EV to EBIT

40.36

EV to EBITDA

17.45

EV to Capital Employed

2.82

EV to Sales

4.60

PEG Ratio

Dividend Yield

ROCE (Latest)

6.99%

ROE (Latest)

6.88%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -13.66% (YoY

-30What is not working for the Company

NET PROFIT(HY)

At CNY 62.04 MM has Grown at -61.39%

INTEREST(HY)

At CNY 9.77 MM has Grown at 35.57%

OPERATING CASH FLOW(Y)

Lowest at CNY 286.13 MM

NET SALES(HY)

At CNY 868.9 MM has Grown at -9.73%

ROCE(HY)

Lowest at 5.35%

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.69 times

INTEREST COVERAGE RATIO(Q)

Lowest at 1,456.29

DEBT-EQUITY RATIO (HY)

Highest at 18.24 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.37 times

OPERATING PROFIT(Q)

Lowest at CNY 69.1 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 14.45 %

Here's what is working for Shenzhen YHLO Biotech Co., Ltd.

Raw Material Cost

Fallen by -13.66% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shenzhen YHLO Biotech Co., Ltd.

Net Profit

At CNY 62.04 MM has Grown at -61.39%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Interest

At CNY 9.77 MM has Grown at 35.57%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest Coverage Ratio

Lowest at 1,456.29

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Sales

At CNY 868.9 MM has Grown at -9.73%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Debtors Turnover Ratio

Lowest at 3.69 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Cash Flow

Lowest at CNY 286.13 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Operating Profit

Lowest at CNY 69.1 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 14.45 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Debt-Equity Ratio

Highest at 18.24 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.37 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio